Efficacy of afatinib for pulmonary adenocarcinoma with leptomeningeal metastases harboring an epidermal growth factor receptor complex mutation (exon 19del+K754E): A case report
1Department of Intervention, Tianjin HuanHu Hospital, Tianjin Key Laboratory of Cerebral Vascular and Neurodegenerative Diseases, Tianjin, China.
Rationale:
Liquid biopsy of cerebrospinal fluid (CSF) and sequencing of cell-free DNA has rarely been used to identify epidermal growth factor receptor (EGFR) mutations, which can guide the design of precise, personalized treatment for patients with leptomeningeal metastasis from lung adenocarcinoma.
Patient Concerns:
A 42-year-old woman with lung adenocarcinoma and leptomeningeal metastasis was admitted to our hospital on March 31, 2019. She exhibited no response to treatment with gefitinib, osimertinib, or chemoradiotherapy and was in critical condition, with an expected survival of <4 weeks.
Diagnosis:
Next-generation sequencing of CSF and peripheral blood samples identified an EGFR complex mutation (exon19del+K754E).
Interventions:
On April 10, 2019, the patient started oral afatinib (40 mg po qd), but she developed a grade III oral mucosal reaction 1 week later. The afatinib dose was reduced to 30 mg po qd.
Outcomes:
At the follow-up examination on May 15, 2019, the patient reported relief from headaches. Enhanced magnetic resonance imaging revealed a reduction in abnormal leptomeningeal enhancement, and the CSF pressure and carcinoembryonic antigen levels were also reduced. The patient continued to respond to afatinib treatment (30 mg once daily) with minimal adverse effects.
Lessons:
This is the first case report of clinical improvement after afatinib treatment in a patient with lung adenocarcinoma and leptomeningeal metastasis harboring an EGFR complex mutation (exon19del+K754E), and thus provides a clinical reference for treatment with afatinib of cancers harboring EGFR compound mutations.
Insights
This case report details a lung adenocarcinoma patient with leptomeningeal metastasis who improved with afatinib treatment targeting a complex epidermal growth factor receptor (EGFR) mutation. This highlights afatinib as a potential therapy for EGFR compound mutations in advanced lung cancer.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Liquid biopsy of cerebrospinal fluid (CSF) is an emerging tool for identifying actionable mutations in leptomeningeal metastasis.
- Epidermal growth factor receptor (EGFR) mutations are crucial targets for personalized lung adenocarcinoma treatment.
- Identifying complex EGFR mutations can guide therapy in advanced lung cancer with leptomeningeal spread.
Observation:
- A patient with lung adenocarcinoma and leptomeningeal metastasis showed no response to standard therapies.
- Next-generation sequencing of CSF identified a complex EGFR mutation (exon19del+K754E).
- Afatinib treatment was initiated, with dose adjustment due to adverse effects.
Findings:
- The patient experienced significant clinical improvement, including headache relief and reduced leptomeningeal enhancement on MRI.
- Cerebrospinal fluid (CSF) pressure and tumor markers decreased.
- Afatinib at a reduced dose demonstrated efficacy with manageable toxicity.
Implications:
- This is the first report of clinical benefit from afatinib in lung adenocarcinoma with leptomeningeal metastasis and a complex EGFR mutation.
- Afatinib provides a potential treatment option for patients with EGFR compound mutations.
- This case underscores the value of liquid biopsy and targeted therapy in managing refractory leptomeningeal metastasis.
More Related Videos
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
